Aled Edwards

Aled Edwards is the founding and current CEO of the Structural Genomics Consortium (SGC), a public-private charitable partnership that generates research tools and knowledge to support basic science and drug discovery.
The SGC is considered a pioneer of open science. Since 2003, under Aled’s leadership, the SGC has adopted a policy not to file for patents on any of its research output. Discoveries from the SGC have led to 40 clinical trials, have helped launch more than 10 companies including Propellon, an Ontario oncology company that was bought by Celgene for up to $1B, the largest pre-clinical deal in Canadian history, and M4K Pharma, the world’s first open science drug discovery company. Aled is one of three Principal Investigators in a TREAT-AD consortium, an NIH-funded initiative to make unpatented and freely-accessible small molecule drug leads for novel Alzheimer’s therapeutic targets.